Cerebrolysin After Stroke: Mixed Evidence

Two different questions

Cerebrolysin has been tested both shortly after ischemic stroke and alongside early rehabilitation. Those settings are related, but their outcomes are not identical. A treatment can fail a combined measure of disability and neurological recovery while producing a signal on a narrower motor task; the endpoint and trial design determine what each result means ^{[1, 2]}.

CASTA enrolled 1,070 patients and assigned 529 to Cerebrolysin and 541 to placebo. Treatment began within 12 hours of symptom onset, both groups also received aspirin, and follow-up lasted 90 days. Its confirmatory endpoint combined three established scales covering disability, daily functioning and stroke severity. The overall comparison was neutral ^[1].

The subgroup signal

After dividing participants by initial severity, investigators reported a favorable trend in the more severely affected subgroup. They also observed a mortality difference in that subgroup. The abstract explicitly describes the analysis as post hoc and calls for confirmation in another trial. A result selected after the primary comparison cannot be presented as though the entire trial demonstrated a survival benefit ^[1].

Subgroup findings can be useful for planning another study, particularly when a biological explanation is plausible. Their evidentiary role remains narrower than a successful prespecified confirmatory endpoint. Reporting the subgroup without the neutral overall result would conceal the central finding of CASTA ^[1].

The rehabilitation result

CARS compared Cerebrolysin with placebo while both groups participated in a standardized rehabilitation program. Treatment began 24 to 72 hours after stroke, and the principal outcome was arm function at day 90, measured with the Action Research Arm Test. The published abstract reports a favorable effect, with a Mann-Whitney estimator of 0.71 and a 95% confidence interval of 0.63 to 0.79 ^[2].

That estimator is not a claim of 71 percent improvement in arm function. It is a statistical measure comparing the distributions of outcomes in the two groups. The authors describe the trial as exploratory and relatively small, and specifically request a larger randomized trial to confirm the result. The trial tested treatment alongside rehabilitation, not treatment replacing rehabilitation ^[2].

A defensible conclusion

The evidence is mixed for identifiable reasons: patient selection, timing, accompanying rehabilitation and the outcome being measured differ. The positive motor-recovery study should remain visible beside the negative larger confirmatory comparison. Choosing only one produces a simpler story than the trials support ^{[1, 2]}.

These stroke trials do not establish a benefit for healthy-person memory, general cognitive enhancement or brain injury of every kind. The Cerebrolysin monograph includes the broader literature and the separate US regulatory record. A clinical result in one setting does not itself establish marketing permission in another country.

Elsewhere in this index